Cannakeys

Unlocking the Science of Cannabis

CK Home / Virodhamine (O-AEA) Cannabinoid Research

Virodhamine (O-AEA) Cannabinoid Research

Virodhamine (O-AEA) Research Dashboard

11

Primary Studies

31

Related Studies

42

Total Studies

Clinical Studies

0

Clinical Meta-analyses

0

Double-blind human trials

0

Clinical human trials

Pre-Clinical Studies

1

Meta-analyses/Reviews

1

Animal studies

9

Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 42 studies associated with Virodhamine (O-AEA).

Here is a small sampling of Virodhamine (O-AEA) studies by title:

  • Virodhamine, an endocannabinoid, induces megakaryocyte differentiation by regulating MAPK activity and function of mitochondria
  • Interactions of endocannabinoid virodhamine and related analogs with human monoamine oxidase-A and -B
  • Endocannabinoid Virodhamine Is an Endogenous Inhibitor of Human Cardiovascular CYP2J2 Epoxygenase
  • Palmitoylethanolamide prevents neuroinflammation, reduces astrogliosis and preserves recognition and spatial memory following induction of neonatal anoxia-ischemia
  • Activation of platelets by the endocannabinoids 2-arachidonoylglycerol and virodhamine is mediated by their conversion to arachidonic acid and thromboxane A2, not by activation of cannabinoid receptors

Components of the Virodhamine (O-AEA) Research Dashboard

  • Top medical conditions associated with Virodhamine (O-AEA)
  • Proven effects in clinical trials for Virodhamine (O-AEA)
  • Receptors associated with Virodhamine (O-AEA)
  • Individual study details for Virodhamine (O-AEA)

Ready to become a subscriber? Go to our PRICING page.

Select New Cannabinoid

Filter Cannabinoid

Members can filter by the following criteria:

  • Study Type
  • Organ Systems
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Virodhamine (O-AEA)

Description of Virodhamine (O-AEA)

Virodhamine is an endocannabinoid that was discovered in by researchers at Eli Lily and Co. (Amy Porter el al. 2002).

Other Names:

Virodhamine

O-arachidonoyl-ethanolamine, O-Arachidonoylethanolamine, Arachidonic Acid-(2-aminoethyl)-ester; (plus numerous other syn.)


Molecular Formula: C22H37NO2


IUPAC Name: 2-aminoethyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate


Source–PubChem

Virodhamine (O-AEA) Properties and Effects

Virodhamine (O-AEA) may: 


  • Produce hypothermia in test animals (Amy Porter el al., 2002)

  • Induce anti-depressive effects in nicotine dependent test animals (Tamaki Hayase, 2008)

  • Relax the human pulmonary artery (H. Kozłowska et al., 2008)

  • Modulates blood pressure and cardiovascular function (Lauren N. Carnevale et al., 2018)

  • Activate GTPgammaS (GTPγS) binding via GPR55 (E. Ryberg et al., 2007)

  • Increase PPAR alpha-driven transcriptional activity (Y. Sun et al., 2007)

Virodhamine (O-AEA) Receptor Binding

Endocannabinoid system (ECS) and Virodhamine (O-AEA): 


  • CB1 partial agonist with in vivo antagonist activity (Amy Porter el al., 2002)

  • CB2 full agonist (Amy Porter el al., 2002)

  • In the periphery O-AEA concentrations were 2- to 9-fold higher than AEA (Amy Porter el al., 2002)


Endocannabinoidome (eCBome) and Virodhamine (O-AEA): 


  • PPAR-Gamma

  • PPAR-alpha

  • GPR-55

Top  

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.